Bayer secured a decisive edge when the Supreme Court ruled Thursday that the company cannot be held liable for failing to warn about cancer risks linked to its Roundup weedkiller.

With the ruling, Bayer can finally move beyond a cloud of legal uncertainty that has dragged its shares down by roughly 30 percent since the first lawsuit surfaced. Investors who have long pushed for a split between the agricultural and pharmaceutical arms now see a clearer path forward.

The court’s decision arrives after Bayer’s $63 billion takeover of Monsanto, a deal many have labeled one of the worst in corporate history. Clarifying Roundup’s legal status could enable Bayer to carve out its agriculture unit, potentially unlocking value for shareholders and reducing exposure to future litigation.

Bayer’s next move will hinge on how quickly it can separate its crop‑seed and pesticide businesses from its pharmaceutical portfolio, a split some analysts say could boost earnings stability. The Supreme Court’s ruling removes a major legal hurdle, giving the company a fresh chance to restore investor confidence.